RxDoctor Payments Data

Krystina Beaman, MD

Internal Medicine · Tulsa, OKNPI 1679816250

Payments from drug & device makers

$2,053in general payments, 2019–2025

Across 117 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$475
  • Exact Sciences$261
  • Pfizer$212
  • Novo Nordisk$181
  • Lilly USA, LLC$181
  • AstraZeneca$180
  • plus $562 from 11 others

What the payments were for

  • Food & beverage$2,053100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,053 in reported general payments places this provider in the 75th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$99,743
Medicare patients
364
Services billed
1,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$128,639
EliquisApixaban70$81,024
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$48,429
MounjaroTirzepatide45$47,965
XareltoRivaroxaban33$36,533
JardianceEmpagliflozin20$30,970
JanuviaSitagliptin Phosphate38$25,865
Humalog Kwikpen U-100Insulin Lispro27$19,170
Atorvastatin Calcium538$12,362
Rosuvastatin Calcium276$11,114
Breo ElliptaFluticasone/Vilanterol24$9,546
MyrbetriqMirabegron12$8,553
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$8,388
PremarinEstrogens, Conjugated20$6,489
Humulin R U-500 KwikpenInsulin Regular, Human11$5,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$181$128,63992 claims
PfizerEliquis, Premarin$212$87,51390 claims
GSKTrelegy Ellipta, Breo Ellipta$141$57,97586 claims
Lilly USA, LLCMounjaro$181$47,96545 claims
Johnson & JohnsonXarelto$55$36,53333 claims
Boehringer IngelheimJardiance$31$30,97020 claims
Astellas Pharma US IncMyrbetriq$43$8,55312 claims
AbbVieSynthroid$475$4,10357 claims
AstraZenecaSymbicort$180$2,74013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →